Article
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.
European journal of cancer (Oxford, England : 1990) - 1 Sept 2022
Abed Afaf, Law Ngie, Calapre Leslie, Lo Johnny, Bhat Vikas, Bowyer Samantha, Millward Michael, Gray Elin S
Abstract excerpt
INTRODUCTION: Biomarkers that predict the risk of immune-mediated adverse events (irAEs) among patients with non-small cell lung cancer (NSCLC) may reduce morbidity and mortality associated with these treatments. METHODS: We carried out high resolution human leucocyte antigen (HLA)-I typing on 179 patients with NSCLC treated with anti-program death (PD)-1/program death ligand (PDL)-1. Toxicity data were collected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.